Gw Pharmaceuticals Plc Stock Book Value Per Share
GW Pharmaceuticals Plc fundamentals help investors to digest information that contributes to GW Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of GWPH Stock. The fundamental analysis module provides a way to measure GW Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GW Pharmaceuticals stock.
GWPH |
GW Pharmaceuticals Plc Company Book Value Per Share Analysis
GW Pharmaceuticals' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current GW Pharmaceuticals Book Value Per Share | 23.70 X |
Most of GW Pharmaceuticals' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GW Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of GW Pharmaceuticals Plc is about 23.7 times. This is 1494.12% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The book value per share for all United States stocks is 98.77% higher than that of the company.
GWPH Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GW Pharmaceuticals' direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GW Pharmaceuticals could also be used in its relative valuation, which is a method of valuing GW Pharmaceuticals by comparing valuation metrics of similar companies.GW Pharmaceuticals is currently under evaluation in book value per share category among related companies.
GWPH Fundamentals
| Return On Equity | -7.92 | |||
| Return On Asset | -3.55 | |||
| Profit Margin | (11.03) % | |||
| Operating Margin | (9.82) % | |||
| Current Valuation | 6.42 B | |||
| Shares Outstanding | 31.54 M | |||
| Shares Owned By Insiders | 0.20 % | |||
| Shares Owned By Institutions | 80.35 % | |||
| Number Of Shares Shorted | 693.73 K | |||
| Price To Earning | 126.70 X | |||
| Price To Book | 9.24 X | |||
| Price To Sales | 12.92 X | |||
| Revenue | 527.2 M | |||
| Gross Profit | 489.67 M | |||
| EBITDA | (39.01 M) | |||
| Net Income | (58.13 M) | |||
| Cash And Equivalents | 486.75 M | |||
| Cash Per Share | 15.53 X | |||
| Total Debt | 43.64 M | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 4.57 X | |||
| Book Value Per Share | 23.70 X | |||
| Cash Flow From Operations | (27.39 M) | |||
| Short Ratio | 1.15 X | |||
| Earnings Per Share | (1.86) X | |||
| Price To Earnings To Growth | 3.61 X | |||
| Number Of Employees | 1.16 K | |||
| Beta | 1.67 | |||
| Market Capitalization | 6.81 B | |||
| Total Asset | 453.18 M | |||
| Retained Earnings | (813.7 M) | |||
| Working Capital | 369.57 M | |||
| Current Asset | 404.52 M | |||
| Current Liabilities | 34.95 M | |||
| Z Score | 93.2 |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in GWPH Stock
If you are still planning to invest in GW Pharmaceuticals Plc check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GW Pharmaceuticals' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |